Keywords: Bayer, Regorafenib, Colorectal cancer, Ph III, Onyx

Bayer halts regorafenib trial for colorectal cancer on good Ph III results

Article | 27 October 2011

Print This

USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced strong results from its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in